Genethon, a French laboratory dedicated to the design and development of gene therapy products for rare diseases, and Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, today announced an expansion of their collaboration to develop a gene therapy approach for Duchenne muscular dystrophy. Microdystrophin has demonstrated significant efficacy in pre-clinical testing*. The agreement between Sarepta and Genethon paves the way for a clinical trial to begin in 2020. (...)
Genethon, which developed the lentiviral vector used and sponsored initial clinical studies, is pleased with the conclusive results of the gene therapy trial underway in the United States and England in X-linked Chronic Septic Granulomatosis (X-CGD), a rare and severe immune dysfunction. Six of the nine patients are free of treatments related to complications generated by the disease. These results have been published in Nature Medicine. Genethon who had conducted initial preclinical and (...)
ALGENTECH, announces the issuance of a key patent in the field of genome editing by the U.S. Patent Office (U.S. patent number 10457950)The technology claimed by the patent amplifies the effectiveness of gene editing in eukaryotic cells and can be applied in synergy with nucleases, including zinc finger nucleases, TALENs, Crispr-Cas9… Read more
Acticor Biotech , a clinical stage biotechnology company dedicated to the acute phase of thrombo-embolic diseases, including stroke, announces its participation to the BOOSTER consortium, dedicated to personalized medicine for the management of stroke in emergency situations.
Certified, the French company PhinC Development, specialized in simulation and modeling strategy for drug development, strengthens its presence in North America to significantly develop its business and increase its turnover.
Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production, today announces it produced the viral vectors used in the gene therapy-based clinical trial in patients with Fanconi anemia. In this study, the authors demonstrate for the first time the production of blood cells derived from the patients genetically corrected stem cells. The work on Fanconi anemia patients is published in Nature (...)
The agenda of this shareholder’s meeting is to amend the Articles of Association in order to create the position of observer on the Board of Directors, and to appoint BOLD - Business Opportunities for L’Oréal Development to this position in accordance with the announcement made at the last fund-raising event.
In line with its commitment to sustainable development, Braskem, the world’s largest biopolymer producer, announces the renewal of its partnership with Altar, a France-based startup specializing in the development of microorganism lineages in automated cultivation systems. Forged two years ago, the partnership strengthens the company’s strategy for the research and development of renewable (...)
Clinical evaluation begins for Diagen™ to take patients’ genomic profiles into account along the nephrology care pathway TRAASER, an innovative startup specializing in medical genomics, announces the start of clinical evaluation for its Diagen™ solution as part of the SAGE project, laureate of Bpifrance’s Digital Innovation Competition organized for France’s “Investments for the Future” program, to develop medical genomics for kidney diseases. In collaboration with the Paris AP-HP public (...)
Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology Service agreement gives Servier access to Yposkesi’s robust production capacity Servier, an international independent pharmaceutical company, and Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, today announce that they have signed a manufacturing service agreement. Servier selected Yposkesi to develop and GMP manufacture lentiviral vectors to support allogenic CAR-T (...)